Previously recorded as Pharmacia Italia S.P.A. (to 2006)
0 patents currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
This portfolio holds none of the 4 US patents in force on its record. from the record
Of the 4 now held by other companies, 3 name Nerviano Medical Sciences SRL as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2009 to 2030.
US 7,728,140
Pyrrolo[2,3-b]pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them
no later than Nov 29, 2027
US 7,632,854
Aminoindazole Derivatives Active as Kinase Inhibitors, Process for Their Preparation and Pharmaceutical Compositions Comprising Them
Apr 4, 2028
US 9,649,380
Compositions Comprising Probiotic and Prebiotic Components and Mineral Salts, with Lactoferrin
Jan 12, 2030
201320172021202520292030
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends no later than Nov 2027 · Medium confidence
The most cited patent in this portfolio, cited by 35 later US patents, top 25% of utility patents granted in 2010 in our data. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Nerviano Medical Sciences S.R.L
Also notable
Ends Jan 2030 · Medium confidence
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2030.
now held by Haleon Italy S.R.L.
Also notable
Ends Apr 2028 · High confidence
Renewed at every maintenance window since the 2009 grant; no more fees are due before its term ends in 2028.
now held by Nerviano Medical Sciences S.R.L
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Also on record: 4 patents in force now held by others · 16 patents ended · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
4 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
5 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.